Depot Injectable Atorvastatin Biodegradable in Situ Gel: Development, Optimization, in Vitro, and in Vivo Evaluation

Overview

Journal Drug Des Devel Ther

Specialty Pharmacology

Date 2016 Feb 9

PMID 26855565

Citations 9

Authors

Tarek A Ahmed

Yasser A Alharby

Abdel-Rahim M El-Helw

Khaled M Hosny

Khalid M El-Say

Affiliations

Soon will be listed here.

Abstract

This study aimed to develop an optimized depot injectable atorvastatin (ATR) biodegradable in situ gel (ISG) system with minimum initial burst using a central composite design. The factors selected were poly (d, l-lactide-co-glycolide) (PLGA) concentration (X1), molecular weight of polyethylene glycol (PEG) (X2), and PEG concentration (X3). The independent variables were the initial burst of ATR after 2 (Y1) and 24 hours (Y2). The optimized formulation was investigated using scanning electron microscopy, Fourier transform infrared spectroscopy, and in vitro drug release in phosphate-buffered saline of pH 7.4 for 72 hours. The in vivo pharmacokinetic study of the optimized ATR-ISG and the corresponding PEG-free ATR-ISG were conducted by intramuscular injection of a single dose (2 mg/kg) of ATR in male New Zealand White rabbits. A double-blind, randomized, parallel design was used in comparison with those of the marketed ATR tablet. Statistical analysis revealed that PLGA concentration and the molecular weight of PEG have pronounced effects on both Y1 and Y2. The optimized formulation was composed of 36.10% PLGA, PEG 6000, and 15.69% PEG, and exhibited characteristic in vitro release pattern with minimal initial burst. Incorporation of PEG in the formulation causes a slight decrease in the glass transition temperature value of PLGA, leading to a slight change in Fourier transform infrared spectroscopy spectrum due to possible interaction. Moreover, scanning electron microscopy photomicrograph showed smooth surface with disappearance of the cracks which characterize the surface of PEG-free formulation. The pharmacokinetic data for the optimized depot injectable ATR-ISG showed a significant (P<0.05) decrease in maximum plasma concentration from 547.62 to 346.84 ng/mL, and increasing time to reach the maximum plasma concentration from 12 to 72 hours in comparison with the marketed tablet. The optimized ATR-ISG formulation has shown minimal initial drug burst which confirms the suitability of the ISG system in the prolongation of drug release in patients with chronic long-term therapy.

Citing Articles

[Effect of P311 microspheres-loaded thermosensitive chitosan hydrogel on the wound healing of full-thickness skin defects in rats].

Zhang Q, Chen C, Xu N, Lyu D, Jia J, Li W Zhonghua Shao Shang Yu Chuang Mian Xiu Fu Za Zhi. 2022; 38(10):914-922.

PMID: 36299202 PMC: 11821312. DOI: 10.3760/cma.j.cn501225-20220414-00135.

Investigation of Alogliptin-Loaded In Situ Gel Implants by 2 Factorial Design with Glycemic Assessment in Rats.

Ibrahim T, Ayoub M, El-Bassossy H, El-Nahas H, Gomaa E Pharmaceutics. 2022; 14(9).

PMID: 36145615 PMC: 9501034. DOI: 10.3390/pharmaceutics14091867.

In Vitro Evaluation of Poly(lactide-co-glycolide) In Situ Forming Gels for Bedaquiline Fumarate Salt and Pharmacokinetics Following Subcutaneous Injection in Rats.

Van Hemelryck S, Wens R, van Poppel H, Luijks M, Shahidi K, Marczak M Pharmaceutics. 2021; 13(8).

PMID: 34452192 PMC: 8400137. DOI: 10.3390/pharmaceutics13081231.

Self-injectable extended release formulation of Remdesivir (SelfExRem): A potential formulation alternative for COVID-19 treatment.

Patki M, Palekar S, Reznik S, Patel K Int J Pharm. 2021; 597:120329.

PMID: 33540028 PMC: 7948064. DOI: 10.1016/j.ijpharm.2021.120329.

An Optimized Surfactant-Based PEG-PLCL In Situ Gel Formulation For Enhanced Activity Of Rosuvastatin In Poloxamer-Induced Hyperlipidemic Rats.

Ahmed T, Mussari M, Abdel-Hady S, El-Say K Drug Des Devel Ther. 2019; 13:4035-4051.

PMID: 31839704 PMC: 6904902. DOI: 10.2147/DDDT.S224442.

References

Chenite A, Chaput C, Wang D, Combes C, Buschmann M, Hoemann C . Novel injectable neutral solutions of chitosan form biodegradable gels in situ. Biomaterials. 2000; 21(21):2155-61. DOI: 10.1016/s0142-9612(00)00116-2. View

Grassi M, Grassi G . Mathematical modelling and controlled drug delivery: matrix systems. Curr Drug Deliv. 2005; 2(1):97-116. DOI: 10.2174/1567201052772906. View

Deadman C, Kellaway I, Yasin M, Dickinson P, Murdan S . An investigation into the influence of drug lipophilicity on the in vivo absorption profiles from subcutaneous microspheres and in situ forming depots. J Control Release. 2007; 122(1):79-85. DOI: 10.1016/j.jconrel.2007.06.013. View

Luan X, Bodmeier R . Modification of the tri-phasic drug release pattern of leuprolide acetate-loaded poly(lactide-co-glycolide) microparticles. Eur J Pharm Biopharm. 2006; 63(2):205-14. DOI: 10.1016/j.ejpb.2005.12.010. View

Ibrahim H, Ahmed T, Hussain M, Rahman Z, Samy A, Kaseem A . Development of meloxicam in situ implant formulation by quality by design principle. Drug Dev Ind Pharm. 2013; 40(1):66-73. DOI: 10.3109/03639045.2012.746360. View

Ahmed T, Ibrahim H, Samy A, Kaseem A, Nutan M, Hussain M . Biodegradable injectable in situ implants and microparticles for sustained release of montelukast: in vitro release, pharmacokinetics, and stability. AAPS PharmSciTech. 2014; 15(3):772-80. PMC: 4037493. DOI: 10.1208/s12249-014-0101-3. View

Pekarek K, Jacob J, Mathiowitz E . Double-walled polymer microspheres for controlled drug release. Nature. 1994; 367(6460):258-60. DOI: 10.1038/367258a0. View

Reagan-Shaw S, Nihal M, Ahmad N . Dose translation from animal to human studies revisited. FASEB J. 2007; 22(3):659-61. DOI: 10.1096/fj.07-9574LSF. View

Wang L, Venkatraman S, Kleiner L . Drug release from injectable depots: two different in vitro mechanisms. J Control Release. 2004; 99(2):207-16. DOI: 10.1016/j.jconrel.2004.06.021. View

10.

Pekkanen J, Linn S, Heiss G, Suchindran C, Leon A, Rifkind B . Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med. 1990; 322(24):1700-7. DOI: 10.1056/NEJM199006143222403. View

11.

Elias-Al-Mamun M, Khan H, Dewan I, Jalil R . In vitro study on tamsulosin release kinetics from biodegradable PLGA in situ implants. Pak J Pharm Sci. 2009; 22(4):360-7. View

12.

Korsmeyer R, Gurny R, Doelker E, Buri P, Peppas N . Mechanisms of potassium chloride release from compressed, hydrophilic, polymeric matrices: effect of entrapped air. J Pharm Sci. 1983; 72(10):1189-91. DOI: 10.1002/jps.2600721021. View

13.

Desai S, Singh P, SIMONELLI A, Higuchi W . Investigation of factors influencing release of solid drug dispersed in inert matrices. 3. Quantitative studies involving the polyethylene plastic matrix. J Pharm Sci. 1966; 55(11):1230-4. DOI: 10.1002/jps.2600551113. View

14.

Gajula R, Pilli N, Babu Ravi V, Maddela R, Inamadugu J, Rao Polagani S . Simultaneous Determination of Atorvastatin and Aspirin in Human Plasma by LC-MS/MS: Its Pharmacokinetic Application. Sci Pharm. 2012; 80(4):923-40. PMC: 3528047. DOI: 10.3797/scipharm.1206-12. View

15.

Shive , Anderson . Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev. 2000; 28(1):5-24. DOI: 10.1016/s0169-409x(97)00048-3. View

16.

Tang Y, Singh J . Controlled delivery of aspirin: effect of aspirin on polymer degradation and in vitro release from PLGA based phase sensitive systems. Int J Pharm. 2008; 357(1-2):119-25. DOI: 10.1016/j.ijpharm.2008.01.053. View

17.

Mallapragada S, Peppas N, Colombo P . Crystal dissolution-controlled release systems. II. Metronidazole release from semicrystalline poly(vinyl alcohol) systems. J Biomed Mater Res. 1997; 36(1):125-30. DOI: 10.1002/(sici)1097-4636(199707)36:1<125::aid-jbm15>3.0.co;2-h. View

18.

Tan L, Venkatraman S, Sung P, Wang X . Effect of plasticization on heparin release from biodegradable matrices. Int J Pharm. 2004; 283(1-2):89-96. DOI: 10.1016/j.ijpharm.2004.06.022. View

19.

Fredenberg S, Wahlgren M, Reslow M, Axelsson A . The mechanisms of drug release in poly(lactic-co-glycolic acid)-based drug delivery systems--a review. Int J Pharm. 2011; 415(1-2):34-52. DOI: 10.1016/j.ijpharm.2011.05.049. View

20.

Patel R, Carlson A, Solorio L, Exner A . Characterization of formulation parameters affecting low molecular weight drug release from in situ forming drug delivery systems. J Biomed Mater Res A. 2010; 94(2):476-84. PMC: 2914550. DOI: 10.1002/jbm.a.32724. View